Single Cell Gene Expression studies are becoming an essential tool for understanding the complex interplay of cells in both healthy and diseased tissue. Thanks to huge strides forward in technologies enabling the partitioning and sequencing of individual cells, we are seeing an explosion of new Single Cell studies across a variety of fields. In many cases, it seems that the ability to produce data is outpacing the ability extract meaning from the data. ROSALIND is seeking to close this gap by accelerating upstream data processing and providing an intuitive user interface for downstream analysis of cell clusters.

ROSALIND utilizes cloud-scale data processing and an intuitive graphical user interface to make processing of 10x Genomics cell ranger datasets both faster and easier. Alignment, quantification, and download of default clustering results can be performed easily by non-expert users without the need for onsite computer processing power.

ROSALIND also supports downstream analysis of cell clusters generated in the 10x Loupe Browser. Cell clusters defined in Loupe can be compared with one another at the level of individual genes, pathways, drugs, other key terms. This unlocks the next era of Single Cell research which will focus on developing deep understanding of the biology of each cell type cluster in a given context and the identification of actionable markers.


Single Cell

We are excited to participate in the Single Cell Sequencing revolution and look forward to building on the capabilities we have already established by responding to the needs of our user base. We encourage you to try ROSALIND’s new Single Cell Analysis features and let us know what you think.  Video tutorials can be found within the ROSALIND user interface and we are available to perform demos of the new functionality.

Schedule A Demo


Related Posts

Jay Gerlach

Written by Jay Gerlach

Jay is Vice President of Strategic Marketing and Alliances at Rosalind. He is passionate about leveraging new technologies to accelerate discovery of new diagnostics and treatments. Previously, he served as Senior Director of Product Management and Business Unit Leader for NanoString’s nCounter business. At NanoString, he led development and commercialization of many new products and also designed and implemented new processes to help the company scale from a small start-up to a public company. Prior to NanoString, Jay worked at PATH in a role focused on establishing public-private partnerships for development of diagnostic tests for infectious diseases in low resource settings around the world. Early in his career he performed genomic and proteomic research at University of Washington, Seattle Biomed, and Ambit Biosciences.